

June 6, 2023

Kidswell Bio Corporation

Code: 4584 (Growth Market, TSE)

Masaharu Tani, President & CEO

Announcement of appointment of New CEO and Board Directors

Tokyo, June 6, 2023 –At the Board of Directors meeting today, Kidswell Bio Corporation (hereafter KWB) resolved to put the appointment of the following President & CEO and Directors of the Board into the agenda of the 23rd ordinary general meeting of shareholders to be held on June 29, 2023.

1. Change of President & CEO

(1) Candidate of President & CEO (To be appointed on June 29, 2023)

Name	Current title	New position
Shinya Kurebayashi	President & CEO	Corporate Officer, Chief Business Officer

(2) Reasons for the appointment

For the achievement of our Mid-Term Strategic Plan -KWB 2.0-, Shinya Kurebayashi has been mainly conducting a wide range of activities in the biosimilar business and the regenerative medicine business, such as searching for new partner companies, negotiating partnerships, strengthening relationships with partners, and raising funds. Under the leadership of Shinya Kurebayashi, KWB will respond to changes in the environment surrounding KWB and make flexible, timely, prompt, and appropriate management decisions and promotions, and improve our corporate value.

(3) Details of new CEO

New title	President & CEO	
Name	Shinya Kurebayashi	
Date of birth	December 28, 1976	
Education	Massachusetts Institute of Technology, MSc, Physics	
Biography	Apr. 2004	Joined Goldman Sachs Japan
	Aug. 2009	Joined Morgan Stanley (Mitsubishi UFJ Morgan Stanley Securities)
	Oct. 2014	Jointed ImPACT of Cabinet Office
	Sep. 2015	Joined Advanced Cell Technology and Engineering LTD (ACTE) as Business Administration Officer
	Jun. 2016	Board Director and Business Administration Officer, ACTE
	Aug. 2016	Board Director and General Manager of Corporate Planning & Business Administration Div., ACTE

	Jan. 2018	Board Director, Executive Vice President, Director of Regenerative Medicine Business Div. and General Manager of Business Div., ACTE
	Mar. 2019	Joined Kidswell Bio Corporation (f/k/a Gene Techno Science Co., Ltd.) as Corporate Officer, Chief Business Officer (To the present)
	Mar. 2021	Board Director, Japan Regenerative Medicine (JRM)
Numbers of shares owned	87,000 shares as of June 6, 2023	

2. Changes of Directors

(1) Director candidates

Name	New title	Current title
Shinya Kurebayashi	President & CEO	Corporate Officer, CBO, Business Development Div.
Masayuki Kawakami	Board Director	Corporate Officer, COO, Research & Development Div.
Norikazu Eiki	Board Director (Outside)	Reappointed

(Note) Norikazu Eiki is a candidate for outside director stipulated in the Companies Act.

(2) Details of New Director of the Board

New title	Director	
Name	Masayuki Kawakami	
Date of Birth	April 10, 1964	
Education	Kyoto Univ. Graduate School of Engineering, Ph.D.	
Biography	Apr. 1989	Joined FUJIFILM Corp.
	Nov. 2001	Visiting Researcher, Kyoto Univ. Department of Synthetic Chemistry and Biological Chemistry
	Apr. 2007	Research Manager, Research laboratories, FUJIFILM Corp.
	Dec. 2009	Manager, FUJIFILM Toyama Chemical Co., Ltd. (f/k/a Toyama Chemical Corp.)
	Apr. 2012	Director, FUJIFILM Pharmaceuticals USA, Inc.
	Apr. 2017	Joined Kidswell Bio Corporation (f/k/a Gene Techno Science Co., Ltd.) as Director of Business Development Div.
	Mar. 2018	Corporate Officer, Chief Technology Office
	Feb. 2020	Board Director, Japan Regenerative Medicine Co., Ltd. (JRM)
	Mar. 2021	President, JRM
	Nov. 2022	Corporate Officer, Chief Operating Officer (To the present)
Numbers of shares owned	2,500 shares as of June 6, 2023	

(3) Reasons for the appointment

For the reason for the appointment of Shinya Kurebayashi, please see “1. Change of President & CEO, (2) Reasons for change” above.

In KWB’s biosimilar business as our revenue foundation, Masayuki Kawakami has engaged in the launch of three biosimilar products that required research and development using advanced biotechnology and has been promoting the establishment of continuous cost reduction. In addition, Masayuki Kawakami has greatly contributed to the progress of the research and development of SHED (stem cells from human exfoliated deciduous teeth) at KWB.

(4) Scheduled Date of Appointment

June 29, 2023, at the 23rd ordinary general meeting of shareholders

5. Resignation

Name	Current title
Masaharu Tani	President & CEO
Aya Chiba	Director

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children’s potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all people under “Kids Well, All Well.”

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com